A new publication on the peptide LL-37 appeared on September 11, 2026, in the International Journal of Biological Macromolecules. The paper, titled "Calmodulin-tagging prevents aggregation and facilitates the proteolytic release of the recombinant human cathelicidin LL-37 by accommodating its hydrophobic regions," was indexed under PubMed ID 42727664.
The title indicates the study addresses a method for producing recombinant human cathelicidin LL-37 using calmodulin-tagging. According to the title, this tagging approach prevents aggregation and facilitates proteolytic release of the peptide by accommodating its hydrophobic regions. No further details of the study's methods, data, or conclusions are provided beyond this title and publication record.
LL-37 remains classified as an unapproved compound used in research settings only. This publication record does not constitute an endorsement of safety, efficacy, or any therapeutic application. No dosing, clinical, or outcome information is included in this event record.
Readers interested in the broader context of this compound can consult the LL-37 overview for additional background information.